Related Experiment Video

Updated: May 23, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

196

High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay

Shuai Zhen1,2

  • 1Center for Translational Medicine, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.

Journal of Medical Virology
|May 22, 2025
PubMed

Insights

Immune checkpoint inhibitors (ICIs) have transformed advanced HPV-related cancer treatment, offering survival benefits where chemotherapy and TKIs failed. Combination therapy with ICIs and bevacizumab shows promise for prolonged overall survival.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Human papillomavirus (HPV)-related cancers often develop with chronic inflammation.
  • Conventional treatments like chemotherapy and tyrosine kinase inhibitors (TKIs) show limited efficacy in advanced HPV-related cancers.
  • Tumor resistance to systemic therapies necessitates novel treatment strategies.

Purpose of the Study:

  • To review the historical development and current status of immune checkpoint inhibitor (ICI) therapy for HPV-related cancers.
  • To summarize recent clinical trials involving ICIs in advanced HPV-related cancers.
  • To explore emerging novel ICIs for future therapeutic advancements.

Main Methods:

  • Literature review of clinical trials and research on ICI therapy in HPV-related cancers.
  • Analysis of treatment outcomes, including survival benefits and resistance patterns.
  • Discussion of combination regimens, such as ICIs with bevacizumab.

Main Results:

  • ICI therapy, including anti-CTLA-4 and anti-PD1/PDL1 agents, has demonstrated survival benefits in patients resistant to sorafenib.
  • Combination therapy of ICIs with bevacizumab has significantly prolonged overall survival (OS) in advanced HPV-related cancers post-sorafenib.
  • Recent trials highlight the evolving landscape of ICI applications in this patient population.

Conclusions:

  • Immune checkpoint inhibitors represent a paradigm shift in treating advanced HPV-related cancers.
  • Optimized combination regimens are crucial for maximizing therapeutic efficacy and patient survival.
  • Ongoing research into novel ICIs holds potential for next-generation checkpoint blockade therapies.
Keywords:
cellular Effectcombination therapy: disease controlhuman papillomavirus: virus classification

More Related Videos

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions13:56

A Comparative Approach to Characterize the Landscape of Host-Pathogen Protein-Protein Interactions

Published on: July 18, 2013

11.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.1K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
319
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K